Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University)

N/A

Report date: 2023/05/05 17:37:14

Base Information

Drug NameAnti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University)
Drug Alias NameLUCAR-20S CAR-T cellsLUCAR-20S
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Legend Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Gao Boren Hospital Co LtdNanjing Legend Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A